Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 11/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16585293 | 0.90 | PAK4 (0.39) | PAK4GABRA5STAT3HPGDKDM4E | |
| SCHEMBL16584923 | 0.90 | PAK4 (0.39) | PAK4GABRA5STAT3HPGDKDM4E | |
| SCHEMBL16584924 | 0.90 | PAK4 (0.39) | PAK4GABRA5STAT3HPGDKDM4E | |
| SCHEMBL18704598 | 0.87 | HPGD (0.43) | PAK4GABRA5STAT3HPGDHSD17B10 | |
| SCHEMBL16585117 | 0.87 | S1PR1 (0.41) | PAK4GABRA5STAT3HRH3 | |
| SCHEMBL16593025 | 0.86 | GABRA5 (0.38) | PAK4GABRA5STAT3HPGD | |
| SCHEMBL16593022 | 0.86 | GABRA5 (0.38) | PAK4GABRA5STAT3HPGD | |
| SCHEMBL16585033 | 0.84 | GABRA5 (0.42) | PAK4GABRA5STAT3 | |
| SCHEMBL16585177 | 0.84 | STAT3 (0.39) | PAK4GABRA5STAT3HPGDLRRK2 | |
| SCHEMBL18542146 | 0.83 | KMO (0.43) | PAK4GABRA5STAT3HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2015042414-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME | Karyopharm Therapeutics Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015042414-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME | Karyopharm Therapeutics Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | PAK4, PAK5, PAK1 | PAK4 1/4885GABRA5 3598/4885STAT3 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.